TY - JOUR AB - Gastric cancer is one of the most common types of cancer; notably, gastric cancer is one of the top five malignancies with regards to incidence and mortality rates. The symptoms of early gastric cancer are not typical, exhibiting only slight upper abdominal discomfort. When the symptoms become more obvious, the lesion has usually progressed to an advanced stage. Notably, >90% of inpatients already have locally advanced or metastatic gastric cancer at the time of initial diagnosis, with limited treatment options for advanced gastric cancer. These options include chemotherapy, targeted therapy and immune checkpoint inhibitors (ICIs). With regards to ICIs, the clinical benefit of monotherapy for advanced gastric cancer is limited; however, combinations of ICIs and other therapies may have clinical benefit. Relevant clinical studies have demonstrated that combinations of ICIs with chemotherapy, anti‑vascular targeted therapy or other molecular targeted therapies, and the use of two ICIs, improve outcomes for patients with advanced gastric cancer. This article is a review of progress in the use of ICIs in combination with other therapies for the treatment of gastric cancer. The purpose of this article was to advance gastric cancer immunotherapy and to improve the overall therapeutic benefit for patients with advanced gastric cancer. AD - Department of Oncology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong 266000, P.R. China AU - Song,Xiaoxu AU - Qi,Weiwei AU - Guo,Jing AU - Sun,Libin AU - Ding,Aiping AU - Zhao,Guanghui AU - Li,Hui AU - Qiu,Wensheng AU - Lv,Jing DA - 2020/10/01 DO - 10.3892/ol.2020.11905 IS - 4 JO - Oncol Lett KW - cancer gastric cancer immunotherapy combination therapy ICIs research progress PY - 2020 SN - 1792-1074 1792-1082 SP - 46 ST - Immune checkpoint inhibitor combination therapy for gastric cancer: Research progress (Review) T2 - Oncology Letters TI - Immune checkpoint inhibitor combination therapy for gastric cancer: Research progress (Review) UR - https://doi.org/10.3892/ol.2020.11905 VL - 20 ER -